Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice

International Journal of Obesity

Volumn 35, Issue 12, 2011, Pages 1539-1548

  Bell Anderson, K S ^a   Aouad, L ^a   Williams, H ^a   Sanz, F R ^a,b   Phuyal, J ^a   Larter, C Z ^c   Farrell, G C ^c   Caterson, I D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONTPELLIER SUPAGRO   (France)

^c The Australian National University   (Australia)

Author keywords

cannabinoid; glucose intolerance; hepatic steatosis; inflammation; obese mouse

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; FAT; INSULIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; EPIDIDYMIS FAT; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID DIET; LIVER; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MICE; OBESITY, MORBID; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

MUS; RODENTIA;

EID: 84856414714     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.55     Document Type: Article

References (30)

1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887. (Pubitemid 46024995)
2. Rutter MK, Meigs JB, Sullivan LM, D'Agostino Sr RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-3257. (Pubitemid 43334382)
3. Oakes ND, Bell KS, Furler SM, Camilleri S, Saha AK, Ruderman NB et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 1997; 46: 2022-2028. (Pubitemid 27512090)
4. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846. (Pubitemid 46024990)
5. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system Am J Med 2007; 120. (9 Suppl 1): S18-S24; discussion S24. (Pubitemid 47284984)
6. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180. (Pubitemid 44271774)
7. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060. (Pubitemid 44923642)
8. Pagotto U, Cervino C, Vicennati V, Marsicano G, Lutz B, Pasquali R. How many sites of action for endocannabinoids to control energy metabolism Int J Obes 2006; 30: S39-S43.
9. Engeli S, Jordan J. The endocannabinoid system: body weight and metabolic regulation. Clin Cornerstone 2006; 8 (Suppl 4): S24-S35.
10. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134. (Pubitemid 41653104)
11. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.[published erratum appears in Lancet. 2005;366(9483):370]. Lancet 2005; 365: 1389-1397. (Pubitemid 40523733)
12. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschop MH. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 2008; 20 (Suppl 1): 147-151. (Pubitemid 351552686)
13. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353. (Pubitemid 36120150)
14. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary- adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403-3410. (Pubitemid 44923599)
15. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1641-1645.
16. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006; 84: 353-359. (Pubitemid 44137303)
17. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471-478. (Pubitemid 43121944)
18. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914. (Pubitemid 36368998)
19. Arsov T, Silva DG, O'Bryan MK, Sainsbury A, Lee NJ, Kennedy C et al. Fat aussie-a new Alstrom syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006; 20: 1610-1622. (Pubitemid 43967568)
20. Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA et al. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes 2005; 54: 1581-1587. (Pubitemid 40586693)
21. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152-1159.
22. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY et al. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-1668.
23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808. (Pubitemid 38063703)
24. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
25. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. (see comment). J Clin Invest 2005; 115: 1298-1305. (Pubitemid 40629049)
26. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46: 122-129. (Pubitemid 47171928)
27. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914. (Pubitemid 36368998)
28. Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM et al. Adiponectin is required to mediate rimonabantinduced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2009; 296: R929-R935.
29. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
30. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010; 59: 926-934.